ストックスクリーナーアプリを入手
14.13
2.96%
-0.41
Atrium Therapeutics Inc (RNA) 最新ニュース
Atrium Therapeutics Inc - Reuters
Fierce Biotech Fundraising Tracker '26: Neomorph nabs $100M; Vivatides' $54M series A - Fierce Biotech
Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN
Atrium Therapeutics Inc. Live Share Prices and Trades. RNA.US Live Streaming Share Prices. - London South East
T. Rowe Price holds 1.55M Atrium shares (10.0%) (NASDAQ: RNA) - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart - Capital.com
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart | Capital.com Australia - capital.com
RNA PE Ratio & Valuation, Is RNA Overvalued - Intellectia AI
Mast Multialternative Strategy Fund's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Atrium Therapeutics, Inc.(NasdaqGS:RNA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stephanie Kenney Net Worth (2026) - GuruFocus
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Rocio Martin Hoyos Net Worth (2026) - GuruFocus
Brendan R. Winslow Net Worth (2026) - gurufocus.com
Atrium Mortgage Investment (TSE:AI) Given a C$13.12 Price Target at Fundamental Research - Defense World
Atrium Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | RNA | US04965N1046 - marketscreener.com
Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks - Citeline News & Insights
Atrium Therapeutics Inc. (NASDAQ: RNA)Share Price and Research - intelligentinvestor.com.au
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Atrium Therapeutics Inc Share Price USD0.001 - Hargreaves Lansdown
Atrium Therapeutics Inc. share price - Capital.com
Atrium Tx launches with Avidity's RNA ticker and cardio assets - bioworld.com
Atrium Therapeutics, Inc. (RNA): An Insightful Analysis of a Biotech Challenger with a $2.28 Billion Market Cap - DirectorsTalk Interviews
Atrium Therapeutics Launches with $270M to Advance RNA Therapies for Rare Genetic Cardiomyopathies - HLTH
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to NASDAQ Composite Index - marketscreener.com
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
RNA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Q4 Earnings Estimate for CVE:DWS Issued By Atrium Research - Defense World
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Finviz
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CMO options cashed out in $72 Novartis buyout - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding - GuruFocus
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates - marketscreener.com
Atrium Therapeutics Launches with $270M - Contract Pharma
Novartis completes acquisition of Avidity Biosciences - TipRanks
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting - TipRanks
[POSASR] Avidity Biosciences, Inc. SEC Filing - Stock Titan
As Novartis deal closes, Avidity's rare heart disease spinout launches with $270M - Endpoints News
0.94%
1.36%
大文字化:
|
ボリューム (24 時間):